# Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

> **NCT04501666** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 286 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Nemolizumab 30 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04501666
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-11
- **Primary completion:** 2022-11-11
- **Final completion:** 2023-02-21
- **Target enrollment:** 286 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501666, "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04501666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*